Breadcrumb Home News News archive A news archive from Sobi in North America News archive A news archive from Sobi in North America Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout 06/15/2020 - 16:06 Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine 05/07/2020 - 08:28 Sobi publishes report for the first quarter 2020 05/05/2020 - 13:24 Load More
Sobi and Selecta announce strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout 06/15/2020 - 16:06
Results from pivotal phase 2/3 study of emapalumab in patients with primary HLH published in New England Journal of Medicine 05/07/2020 - 08:28